Endeavor Biomedicines vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Endeavor Biomedicines is a Cambridge-based clinical-stage biotech targeting drivers of fibrosis and oncology with precision small molecules; raised $450M in a 2024 Series B led by Arch Venture Partners and GV;
About
Endeavor Biomedicines is a clinical-stage biotechnology company founded in 2022 and headquartered in Cambridge, Massachusetts, that is developing precision small-molecule medicines targeting the molecular drivers of fibrotic diseases and cancer. The company's scientific focus is on identifying and inhibiting protein targets that are specifically activated in disease states — particularly in idiopathic pulmonary fibrosis (IPF), a fatal scarring lung disease, and solid tumor oncology. Endeavor's platform emphasizes structural biology and medicinal chemistry to design compounds with high selectivity for disease-driving targets, minimizing off-target effects that have limited the tolerability of earlier investigational drugs. The company is led by CEO Tomas Kiselak and supported by a scientific advisory board of leading experts in fibrosis and cancer biology.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.